International collaboration of three ‘giants’ with the G7 countries in emerging nanobiopharmaceuticals

Nanobiopharmaceuticals is a hopeful research domain from recent scientific advances with massive marketable potential. Although some researchers have studied international collaboration from some aspects, few articles are as comprehensive as this article to consider international cooperation from so many different aspects. We lay more emphasis on international collaboration in the field of nanobiopharmaceuticals involving China. Incremental citation impact values show that in order to move forward and improve the overall competitiveness in the field, China requires to carry out more international collaboration in the field, especially with USA, Germany, and England. Startlingly, multinational collaboration does not sway Chinese citation impact as much as we anticipate in the field. China has reached the first rank in the world in terms of publication amount per year in the field in 2009. Few papers about international collaboration compare small world phenomenon. We use small world quotient to find that it is important for Chinese international co-authors to strengthen to cultivate a cooperation networks in which a node’s partners are also buddies to each other.